센츄리 테라퓨틱스(IPSC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.85 (-1.60%), 시가총액 $0.42B, 52주 최저~최고 $0.46 ~ $2.94.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-
센츄리 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
센츄리 테라퓨틱스의 현재 주가는 $1.85 (-1.60%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
센츄리 테라퓨틱스의 시가총액은 약 $0.42B입니다.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its